DCLRE1B and neoplasm: According to the outcomes, DCLRE1B expression had a positive link to CAFs in ACC, KICH, KIRC, KIRP, PAAD, PCPG, THCA, and UCS using Tumor Immune Dysfunction and Exclusion (TIDE) algorithm (Figs. 6A-B), highlighting that DCLRE1B might be utilized as a target for treating these cancers.